News & Updates
Filter by Specialty:
Febuxostat vs benzbromarone: Which is more effective in CKD with hyperuricaemia, hypertension?
Treatment with either febuxostat or benzbromarone results in comparable outcomes among patients with stage G3 chronic kidney disease (CKD) with asymptomatic hyperuricaemia and hypertension, a study has shown.
Febuxostat vs benzbromarone: Which is more effective in CKD with hyperuricaemia, hypertension?
13 Aug 2023
Progesterone may raise chances of having a baby for couples with unexplained infertility
Couples with unexplained infertility who are seeking parenthood may benefit from progesterone treatment, which can increase the livebirth rates and decrease miscarriage rates by twofold, according to data from the PiNC* trial.
Progesterone may raise chances of having a baby for couples with unexplained infertility
13 Aug 2023
Camrelizumab plus chemo combo beneficial in Asian patients with advanced NSCLC
Adding camrelizumab to platinum-based chemotherapy in the neoadjuvant treatment setting appears to improve the rate of pathologic complete response (pCR) in Asian patients with stage IIIA or IIIB non–small cell lung cancer (NSCLC), with manageable toxicity, according to data from the phase II TD-FOREKNOW study.
Camrelizumab plus chemo combo beneficial in Asian patients with advanced NSCLC
10 Aug 2023
Fosaprepitant dosing frequency makes no difference in CCRT-induced nausea, vomiting prevention
For patients undergoing concurrent chemoradiotherapy (CCRT), treatment with either weekly or every-3-weeks fosaprepitant helps reduce nausea and vomiting caused by CCRT, with no difference in the effect, as reported in a study.
Fosaprepitant dosing frequency makes no difference in CCRT-induced nausea, vomiting prevention
09 Aug 2023
Second-line avelumab works against dMMR/MSI metastatic colorectal cancer
Treatment with the immune checkpoint inhibitor avelumab in the second-line setting confers survival and disease control benefits in patients with deficient mismatch repair and/or microsatellite instability (dMMR/MSI) metastatic colorectal cancer (mCRC) when compared with standard treatment, with a favourable safety profile, according to the results of the phase II SAMCO-PRODIGE 54 trial.
